# American Society of Clinical Oncology (ASCO)

Source: https://onco.cc/institutions/asco/  
OnCo record `asco` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ASCO is the world's largest oncology professional society; its annual meeting each June is where most practice-changing trials are first presented.

## Summary

The American Society of Clinical Oncology, based in Alexandria, Virginia, is the world's largest oncology professional society, and its Annual Meeting each June, with around forty thousand attendees, is where most practice-changing trials are first presented. It publishes the Journal of Clinical Oncology and its JCO sister journals, runs the TAPUR basket trial and CancerLinQ, and issues clinical practice guidelines including the 2021 guideline on immune-related side effects. OnCo connects it to bottlenecks on hidden failures and incentives that reward marginal gains, and to ideas such as a guideline fast track for repurposed drugs and independent validation of surrogate endpoints. Whether a society funded partly by industry can police value is the fair question. Its guidelines collection has its own page.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Alexandria, VA, US
- Type: consortium
- Website: https://www.asco.org

## Sources

- Official website: https://www.asco.org

## Connected records

- collections: [ASCO clinical practice guidelines](https://onco.cc/collections/asco-guidelines/), [ASCO Daily News](https://onco.cc/collections/src-asco-daily-news/), [ASCO Meeting Library](https://onco.cc/collections/src-asco-meeting-library/), [The ASCO Post](https://onco.cc/collections/src-asco-post/)
- people: [Clifford A. Hudis](https://onco.cc/people/clifford-hudis/), [Eric J. Small](https://onco.cc/people/eric-small/), [Everett E. Vokes](https://onco.cc/people/everett-vokes/), [Jane Cooke Wright](https://onco.cc/people/jane-cooke-wright/), [Lori J. Pierce](https://onco.cc/people/lori-pierce/), [Lynn M. Schuchter](https://onco.cc/people/lynn-schuchter/), [Robin T. Zon](https://onco.cc/people/robin-zon/)
- journals: [American Society of Clinical Oncology educational book](https://onco.cc/journals/asco-educational-book/), [JCO clinical cancer informatics](https://onco.cc/journals/jco-clinical-cancer-informatics/), [JCO global oncology](https://onco.cc/journals/jco-global-oncology/), [JCO Oncology Practice](https://onco.cc/journals/jco-oncology-practice/), [JCO Precision Oncology](https://onco.cc/journals/jco-precision-oncology/), [Journal of Clinical Oncology](https://onco.cc/journals/jco/)
- key papers: [American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer](https://onco.cc/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/), [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/), [Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline](https://onco.cc/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/), [Metastatic Pancreatic Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/), [Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline](https://onco.cc/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/), [Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update](https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/), [Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update](https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- ideas: [A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer](https://onco.cc/ideas/idea-reg-guideline-fast-track-repurposed/), [A public equity index for trial sites and sponsors, tied to funding](https://onco.cc/ideas/idea-tr1-site-equity-index/), [A structured registry for every off-label cancer drug use](https://onco.cc/ideas/idea-data-off-label-outcomes-registry/), [Agree in advance how to borrow evidence between similar rare cancers](https://onco.cc/ideas/idea-bio2-bayesian-borrowing-acceptance/), [An independent programme that validates surrogate endpoints, setting by setting](https://onco.cc/ideas/idea-tr1-surrogate-validation-programme/), [Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales](https://onco.cc/ideas/idea-reg-price-anchored-to-mcbs/), [Default-inclusive eligibility: sponsors must justify every exclusion criterion](https://onco.cc/ideas/idea-tr1-justify-every-exclusion/), [End the abstract-to-paper gap: require full results with any conference presentation](https://onco.cc/ideas/idea-data-full-data-with-abstract/), [Every payer covers routine care costs for trial participants, in every country](https://onco.cc/ideas/idea-tr1-universal-routine-cost-coverage/), [Exempt oncologists who follow the pathway from prior authorisation](https://onco.cc/ideas/idea-cost-gold-card-oncology/), [Fund investigators from under-represented communities and community sites to lead trials](https://onco.cc/ideas/idea-tr1-diverse-investigator-pipeline/), [Funded research pathways for surgeon-scientists and radiation oncologist-scientists](https://onco.cc/ideas/idea-fund-surgeon-scientist-pathway/), [Give negative trials plenary slots at the big cancer conferences](https://onco.cc/ideas/idea-tr2-negative-plenaries/), [Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance](https://onco.cc/ideas/idea-tnbc-pd-l1-assay-harmonisation/), [Just-in-time site activation: open a site in two weeks when a patient appears](https://onco.cc/ideas/idea-tr1-just-in-time-site-network/), [Launch prices indexed to the ESMO benefit scale, revisited when survival matures](https://onco.cc/ideas/idea-fund-mcbs-linked-pricing/), [Lay trial navigators funded per centre, evaluated in a randomised trial](https://onco.cc/ideas/idea-tr1-lay-trial-navigators/), [Living guidelines published as versioned, computable rules](https://onco.cc/ideas/idea-data-computable-living-guidelines/), [Living, machine-readable guidelines pushed to the point of care in every country](https://onco.cc/ideas/idea-moon-living-machine-readable-guidelines/), [Make early palliative care and a goals conversation part of every advanced-cancer pathway](https://onco.cc/ideas/idea-cost-early-palliative-default/), [Micro-learning pushed to community oncologists within 30 days of a practice change](https://onco.cc/ideas/idea-data-thirty-day-practice-change-learning/), [Offline decision support for generalists treating common cancers in low-resource settings](https://onco.cc/ideas/idea-data-offline-cds-lmic-generalists/), [Pay oncologists for the time it takes to enrol a patient](https://onco.cc/ideas/idea-tr1-protected-physician-time-for-enrolment/), [Power trials to detect a benefit patients would value, not the smallest detectable one](https://onco.cc/ideas/idea-tr1-power-for-meaningful-benefit/), [Price a cancer drug by how well it works in each cancer](https://onco.cc/ideas/idea-cost-indication-based-pricing/), [Real-time guideline-concordance feedback for every cancer centre](https://onco.cc/ideas/idea-data-guideline-concordance-dashboards/), [Stop excluding brain metastases from cancer trials](https://onco.cc/ideas/idea-bio2-cns-cohort-mandate/), [Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis](https://onco.cc/ideas/idea-tr1-prior-cancer-hiv-hepatitis-inclusion/), [Tie coverage and copays to the ESMO benefit scale](https://onco.cc/ideas/idea-cost-value-scale-in-coverage/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Failures are hidden](https://onco.cc/bottlenecks/b-negative-results/), [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Pain relief and palliative care are unavailable to most](https://onco.cc/bottlenecks/b-palliative/), [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- institutions: [American Society for Radiation Oncology](https://onco.cc/institutions/astro/), [American Society of Hematology](https://onco.cc/institutions/ash/), [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [HL7 International](https://onco.cc/institutions/hl7/), [International Association for the Study of Lung Cancer](https://onco.cc/institutions/iaslc/), [Japanese Society of Medical Oncology](https://onco.cc/institutions/jsmo/), [Multinational Association of Supportive Care in Cancer](https://onco.cc/institutions/mascc/), [Society for Immunotherapy of Cancer](https://onco.cc/institutions/sitc/), [Society of Surgical Oncology](https://onco.cc/institutions/sso/)
- trials: [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/)

---
JSON: https://onco.cc/api/v1/entities/asco.json